June 05, 2026
9 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
The recent federal reforms to pharmacy benefit managers are a meaningful step in the right direction, but the work is not over yet, according to experts.In January 2025, the Federal Trade Commission released a report that revealed pharmacy benefit managers (PBMs) overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in
June 05, 2026
9 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Potential Big Impact If Firms That Own PBMs Have To Break Up

States already have pharmacy deserts. PBM reforms make it worse

It’s time for Congress to end Big Pharma’s war on generics

New surprise billing fix may not reduce disputes

Trump must crack down on middlemen amid drug affordability crisis

Benefits1™.Medicare from Simplify Healthcare® Powers More Than 30% of CMS PBP Submissions for the Eighth Consecutive Year

PBIRx Hosts Webinar: Biosimilars - The New Savings Frontier for Prescription Drug Benefits

Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

Will Makary's FDA voucher program survive?

Medicare’s mum on GLP-1s, and Massachusetts sues United

While PBM reforms that passed earlier this year will spur further changes in the way business is conducted, it’s anti-trust…

Pharmacy benefit managers have become popular punching bags, primarily because of spread pricing and steering patients to…

A bipartisan group of lawmakers in both chambers of Congress has reintroduced a bill aimed at barring companies from owning both…

More than 90% of employers agreed a rebate-free approach is easier to understand and would improve drug price transparency,…

Trump’s executive order on drug pricing means PBM reform is no longer some niche healthcare conversation happening among wonks.

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot…